Health Kick Podcast: Neurizon Therapeutics
In this episode, Tim speaks with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn about the company's research on motor neurone disease and its drug development of NUZ-001 to treat ALS.
NUZ-001 is developed from monepantel, a drug which originated in veterinary practise as a drench for the treatment and control of gastrointestinal roundworms in sheep.
ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.
Neurizon has now developed a liquid formulation of NUZ-001 to improve patient access and experience.
Tune into the podcast to hear more.
This podcast was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
Originally published as Health Kick Podcast: Neurizon's ALS push and trial plans
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
2 hours ago
- News.com.au
Morgans spotlights nine healthcare stocks with upcoming catalysts after 'upbeat' Bioshares Biotech Summit
Morgans' Scott Power describes mood at Bioshares Biotech Summit as "markedly more upbeat than prior years" with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-term catalysts over next three to six months Results from Argenica's phase II trial of lead product ARG-007 in acute ischaemic stroke patients expected in early September In a further positive sign the ASX healthcare sector may be recovering, Morgans' senior healthcare analyst Scott Power has returned from the 19th annual Bioshares Biotech Summit, describing the mood of presenting companies as "markedly more upbeat than prior years". The summit, which featured presentations from more than 30 biotech companies, followed a strong July for the healthcare sector, which rose 9.05% to be best performer of the 11 ASX sectors. While healthcare remains the worst-performing sector YTD, up just 1.81%, the solid July results and positive momentum at this year's Bioshares conference signals a positive turnaround. Attended by analysts along with institutional and high net worth investors, Stockhead's Tim Boreham refers to the summit as the "Druggies & Dealers' conference – a playful nod to the well-known annual Diggers & Dealers mining forum, which this year fell in the same week. "The conference was centred on the evolution and strategic positioning of Australian biotech companies across the drug development lifecycle, with a strong emphasis on innovation and commercialisation," Power said. "We generally got the sense there is a lot more happening in the background for many of these companies than first glance." Power has highlighted nine ASX healthcare companies presenting at the summit with clear near-term catalysts over the next three to six months. Morgans nine ASX healthcare stocks with upcoming catalysts Neuren Pharmaceuticals (ASX:NEU) Market cap: $2.2 billion Neuren develops drugs for the treatment of neurological disorders and became the darling of the ASX biotech sector in 2023 when trofinetide, marketed as DAYBUE, received US Food and Drug Administration approval as the first and only approved treatment for Rett syndrome – a rare neurological disorder mostly affecting girls and emerging in infancy. Acadia Pharmaceuticals, Neuren's partner, markets DAYBUE in North America with the Aussie biotech eligible to receive double-digit royalties payments. Power said the key upcoming catalyst for Neuren would be an expectation of continued improvement in DAYBUE net sales in Q3 CY25. The company's latest quarterly sales were US$96.1 million, up 14% on pcp. CogState (ASX:CGS) Market cap: $295.9 million Cogstate is a neuroscience technology company focused on optimising neurological health assessments to advance the development of new medicines and deliver clinical insights into brain function. Its Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of neurological performance, including processing speed, attention, visual learning, working memory and executive function. CogState has provided FY25 guidance of revenue between US$52 to US$54 million, up 20% to 24% and profit before tax between US$12 to US$14 million. "CGS will report its FY25 result on August 22 with the existing share buyback expected to be extended," Power said. Market cap: $95m The key upcoming catalyst for Argenica is results forecast for early September of a phase II trial of its lead product ARG-007 in acute ischaemic stroke patients. ARG-007 is a synthetic peptide designed to protect brain cells from dying in the critical minutes and hours after acute neurological events such as stroke, traumatic brain injury (TBI) and hypoxic brain damage. In April, Argenica completed dosing of 92 patients in the double-blinded, randomised, placebo controlled phase II trial undertaken at eight emergency departments around Australia. Data-read out from the trial is due in September with safety the main endpoint, determining if the drug asset can advance further in clinical development. Blinklab (ASX:BB1) Market cap:$55m Blinklab is a company founded by neuroscientists at Princeton University and has developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia and other neurodevelopmental conditions. "The key short term catalyst is the release of results for BB1's pilot study for autism involving around 190 children," Power said, "The study undertaken at two sites is on track to finish recruitment in August with data locking and unblinding to follow and results expected to be released in September. "A main phase trial is expected to follow recruiting up to 900 children across eight additional sites." Clever Culture Systems (ASX:CC5) Market capitalisation $62.4 million Adelaide-based Clever Culture Systems has developed the only US FDA-cleared AI technology for automated culture plate reading. Its APAS (automated plate assessment system) Independence instruments automatically analyse culture plates to detect microbial contamination, classifying growth as significant or non-significant. In sterile drug manufacturing, culture plates are used inside cleanrooms to monitor for contamination, with results critical to releasing safe and effective drugs. Clever Culture's APAS Independence reduces the time consuming manual analysing of the culture plates by microbiologists. "CC5 has signed up three large pharmaceutical companies including AstraZeneca, Bristol Myers Squibb and Novo Nordisk plus two large lab companies and is in negotiations with other tier one groups," Power said. "Announcements around additional customers or expansion with existing customers is a key short-term catalyst." Tetratherix (ASX:TTX) Market cap: $215 million Wound management house Tetratherix made its ASX debut on June 30, breaking an IPO drought for the sector. Barrenjoey Markets and Morgans Financial were joint lead managers and underwriters to the Tetratherix IPO. Tetratherix has developed a proprietary polymer platform enabling the targeted delivery of cells, drugs and biologics, to treat a range of conditions across tissue spacing, bone regenerative and tissue healing. The company will post its maiden FY25 result in late August. "The near-term catalysts we expect to be called out include progress on the bone regeneration franchise which is targeting FDA clearance in H2 CY26 and an update on the recruitment in the trial for Cohort 2 using TetraDerm (tissue healing) involving surgical incisions in the face and neck," Power said. Micro-X (ASX:MX1) Market cap: $52 million Micro-X has proprietary cold cathode, carbon nanotube (CNT) emitter technology which is focused on medical imaging and security applications. The company recently announced a significant commercial milestone, a three-year supply agreement with a major US healthcare provider for its Rover Plus mobile radiology system. The deal followed a successful evaluation and competitive tender by the healthcare provider, which operates more than 700 facilities nationwide. It has added Rover Plus to its approved procurement list, allowing member hospitals to purchase the system without further evaluation or tendering. "We expect additional supply agreements will be executed over the near-term," Power said. Dimerix (ASX:DXB) Market cap: $300m Dimerix's lead drug candidate DMX-200 is in a phase III trial for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The ACTION3 phase III trial continues to recruit across clinical sites globally, with more than 190 sites activated. Full targeted recruitment of 286 patients for the ACTION3 trial is expected to be completed by the end of CY25. Dimerix is also developing DMX-700 for respiratory disease. "Following a positive interim analysis (Part 1) another interim analysis (Part 2) is expected to be released late CY25 or early CY26," Power said. Artrya (ASX:AYA) Market cap: $148m Artrya is developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software called Salix analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya has three key modules in its Salix platform. The FDA-cleared and launched Coronary Anatomy module is already in market. Power said upcoming catalysts for the company included FDA clearances of its Coronary Plaque module, expected in Q3 CY25, and its Coronary Flow module, anticipated in Q1 CY26. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Herald Sun
20 hours ago
- Herald Sun
Imagion teams up with Wayne State University for AI push into cancer detection
Imagion to collaborate with MRI experts at Wayne State University to strengthen push into AI-enabled cancer diagnostics Collaboration will establish optimised imaging protocols for Imagion's MagSense molecular-imaging-agent tech Bolsters relationship Imagion has with Siemens Healthineers, the leading manufacturer of MRI equipment Special Report : Imagion Biosystems has strengthened its push into AI-enabled cancer diagnostics through a new collaboration with leading MRI experts at Wayne State University School of Medicine in the US. Imagion Biosystem (ASX:IBX) has signed a collaborative service agreement with Dr Mark Haacke and Dr Sagar Bush to establish optimised imaging protocols for its proprietary MagSense molecular imaging agent technology. The collaboration further bolsters the existing relationship Imagion has with Siemens Healthineers, the world's leading manufacturer of MRI equipment. Both researchers have had a long-standing collaboration with Siemens and are equipped with its top-of-the-line scanners. The research will focus on quantitative MRI sequences compatible with Siemens and other commercially available MRI scanners. By combining advanced quantitative imaging with the MagSense agents, Imagion aims to enable AI-based interpretation and deliver more accurate and precise data cancer detection and patient care. With Siemens' backing, Imagion plans to incorporate the optimised MRI sequences developed by the leading researcher into its upcoming phase II clinical trial for its HER2 breast cancer imaging agent. Other key objectives of the collaborative service agreement also include: Determining the lowest dose of the MagSense imaging agent to achieve detection Establish MRI sequences and protocols optimised for MagSense Transferring the optimised protocols to clinical sites for use in the planned MagSense HER2 Phase 2 study Using quantitative imaging techniques that could net AI compatible image data to improve diagnostic accuracy 'Exciting development for the medical imaging field' Haacke has been a pioneer in the field of quantitative MRI for decades. Collaboration with his team is set to lay the foundation for future automated analysis of MagSense images using AI. By implementing quantitative MR imaging techniques, Imagion said the specific signature of MagSense imaging agents will be uniquely detectable in affected tissue. By applying advanced post-processing techniques and AI interpretation to these images, MagSense has potential to enable not only automatic detection and differentiation of normal versus cancerous tissue, but also improved staging, tracking and treatment monitoring. 'Imagion's MagSense imaging agents are a very exciting development for the medical imaging field as it finally brings molecular specificity to MRI,' said Haacke. 'I have spent decades developing quantitative, high-resolution imaging to identify new biomarkers and explore disease etiology. 'Working with Imagion is a natural extension of that work, adding increased specificity to the already high resolution and sensitivity of MRI and powering the future of AI-based diagnostics.' Listen : Tim Boreham interviews IBX Solving a key barrier holding back AI diagnostics Imagion said conventional MRI, while producing excellent images of soft tissue, is qualitative by nature. This means it relies on subjective interpretation by radiologists to make a diagnostic determination based on differences in contrast of the various tissues. As a result, imaging findings still require confirmatory biopsies to achieve diagnostic certainty, creating challenges in analysing small lesions or early-stage disease. The lack of specificity is considered a fundamental hurdle for radiologic AI models, limited in their diagnostic capability due to subjectivity of the training data and accuracy of the readers' interpretation. Quantitative imaging, on the other hand, provides specific information about tissue characteristics on a pixel-by-pixel basis. These imaging techniques can measure precise amounts of elements such as iron, water, calcium, or fat in each region of interest. Imagion said that combining quantitative MRI sequences with its MagSense imaging agent could overcome one of the biggest obstacles to AI in medical imaging. MagSense particles attach to cancer cells, creating a unique, measurable signal that can be distinguished from healthy tissue automatically. This could lead to earlier and more accurate cancer diagnoses, reduce differences in how individual radiologists interpret scans, and make advanced imaging available beyond specialised medical centres The company said including these quantitative sequences in its phase II trial for HER2 breast cancer will accelerate development of AI diagnostics by providing early data to train and refine AI models. Exciting time for Imagion Imagion chief business officer Ward Detwiler said the company was very excited to have the collaboration and support of Haacke's research team. 'Dr Haacke literally wrote the book on MRI, which anyone in the MRI space will recognise as required reading,' he said. 'Combining their knowledge and expertise in quantitative MRI with the specificity of our targeted MagSense imaging agents, we believe we can significantly improve the diagnostic utility of the images by introducing quantitative data to enable precise, AI-based detection.' This article was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Imagion teams up with Wayne State University for AI push into cancer detection
The Australian
3 days ago
- The Australian
Health Kick Podcast: Alterity Therapeutics
Stockhead's health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler, who sheds light on a little-known but devastating neurological condition, multiple system atrophy (MSA). MSA may not have the public awareness of Parkinson's or ALS, but it's every bit as serious, and Alterity is aiming to change that. With no approved treatments currently available, MSA represents a major unmet clinical need. Alterity's lead candidate, ATH434, is designed to address a unique biological mechanism involving iron imbalance in the brain. Tune in to hear how ATH434 is showing promise in slowing disease progression, the science behind iron maldistribution in neurodegenerative disease, and how Dr Stamler's decades of FDA drug development experience is helping drive this program forward. This podcast was developed in collaboration with Alterity Therapeutics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
